SUPN Average Annual Return 10 Years
SUPN Average Annual Return Chart 10 Years
Growth of $10,000.00
Without Dividends Reinvested Into SUPN

Also see:
• SUPN stock yearly return 2014
• SUPN stock yearly return 2015
• SUPN stock yearly return 2016
• SUPN stock yearly return 2017
• SUPN stock yearly return 2018
• SUPN stock yearly return 2019
• SUPN stock yearly return 2020
• SUPN stock yearly return 2021
• SUPN stock yearly return 2022
• SUPN stock yearly return 2023
• SUPN YTD return
Average Annual Return Benchmarks
Compare SUPN average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
SUPN Share Performance
SUPN Average Annual Return Table 10 Years
Start date: 04/25/2014
End date: 04/24/2024
Start price/share: $7.68
End price/share: $30.26
Dividends collected/share: $0.00
Total return: 294.01%
SUPN Average Annual Return: 14.69%
Starting investment: $10,000.00
Ending investment: $39,407.76
Years: 10.01


SUPN average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
About Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. Co.'s products include Trokendi XR and Oxtellar XR, which are the once-daily extended release topiramate and oxcarbazepine products indicated for the treatment of epilepsy; APOKYN, which is a product indicated for the intermittent treatment of hypomobility or off episodes in patients with Parkinson's Disease (PD); XADAGO, which is an once-daily product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD; and MYOBLOC, which is a product indicated for the treatment of cervical dystonia and sialorrhea in adults. The SUPN average annual return 10 years is shown above.

The Average Annual Return on the SUPN average annual return 10 years page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether SUPN average annual return 10 years or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the SUPN average annual return calculation with any dividends reinvested as applicable (on ex-dates).
SUPN Current Stock Quote
Quotes delayed 20 minutes

Email EnvelopeFree SUPN Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
Featured Slideshows
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!
Video: Don't Forget Dividends in Average Annual Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Average Annual Return Peers
Supernus Pharmaceuticals (SUPN) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

SVRA Average Annual Return
SWAV Average Annual Return
SWTX Average Annual Return
SXTP Average Annual Return
SYBX Average Annual Return
SYK Average Annual Return
SYRE Average Annual Return
SYRS Average Annual Return
TARA Average Annual Return
TARO Average Annual Return
More Healthcare companies »

★★★★★ Based on a ranking of our entire coverage universe by highest ten year average annual return, Supernus Pharmaceuticals (SUPN) ranks in the top 25% of all stocks whose returns we have reviewed.
What has the average annual return been for SUPN over the past ten years?
✔️Accepted answer: The ten year SUPN average annual return has been 14.69%.

What start date was used in your SUPN average annual return calculation?
✔️Accepted answer: The start date was 04/25/2014.

What end date was used in your SUPN average annual return calculation?
✔️Accepted answer: The end date was 04/24/2024.

If I had invested $10,000 into SUPN ten years ago, how much would I have today?
✔️Accepted answer: Today, as of 04/24/2024, you would have $39,407.76.

What does that work out to on a total return basis?
✔️Accepted answer: The SUPN ten year total return ending 04/24/2024 works out to 294.01%.


Also see:
• SUPN stock yearly return 2014
• SUPN stock yearly return 2015
• SUPN stock yearly return 2016
• SUPN stock yearly return 2017
• SUPN stock yearly return 2018
• SUPN stock yearly return 2019
• SUPN stock yearly return 2020
• SUPN stock yearly return 2021
• SUPN stock yearly return 2022
• SUPN stock yearly return 2023
• SUPN YTD return
 

SUPN Average Annual Return 10 Years | www.AverageAnnualReturn.com | Copyright © 2021 - 2024, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.